FINWIRES · TerminalLIVE
FINWIRES

BOM:532872

2 stories mentioning BOM:532872

Every FINWIRES story that references BOM:532872, newest first.

Asia

Indian Indices Fall on Thursday as Crude Surge, Global Cues Weigh

Indian equities ended lower on Thursday as a broad-based selloff, rising crude oil prices and weak global cues weighed on sentiment.Continued foreign outflows also added pressure on the benchmarks.The BSE Sensex fell 582.86 points, or 0.8%, to close at 76,913.50, while the NSE Nifty declined 180.10 points, or 0.7%, to 23,997.55.Brent crude rose about 5% to $124 per barrel, raising concerns over inflation and growth for India, a major oil importer. The spike followed discussions by U.S. President Donald Trump with oil companies over potential supply disruptions linked to the prolonged blockade of Iranian ports.In corporate developments, Hindustan Unilever (NSE:HINDUNILVR, BOM:500696) fell nearly 3% even as it reported an increase in consolidated profit rose to 29.9 billion Indian rupees. Revenue from operations also increased to 161.7 billion Indian rupees from 149.6 billion rupees a year ago.Sun Pharma Advanced Research (NSE:SPARC, BOM:532872) declined about 4% after announcing the sale of a U.S. FDA-granted priority review voucher for $195 million. The proceeds are expected to support pipeline development and innovation strategy, the company said.

^BSENifty 50BOM:500696BOM:532872NSE:HINDUNILVRNSE:SPARC
Asia

Sun Pharma Advanced to Sell Rare Paediatric Disease Priority Review Voucher for $195 Million

Sun Pharma Advanced Research Company (NSE:SPARC, BOM:532872) has agreed to sell its rare paediatric disease priority review voucher (PRV) granted by the U.S. Food and Drug Administration ( US FDA) for the approval of Sezaby for $195 million.PRV was granted by the US FDA for the approval of Sezaby, used to treat neonatal seizures. It is a benzyl alcohol and propylene glycol-free formulation of phenobarbital sodium powder for injection, according to a Thursday filing to the Indian stock exchanges.The sale of the PRV is expected to help the company develop its pipeline assets and strengthen its external innovation strategy.The transaction is subject to customary closing conditions, including expiration of the applicable waiting period.

BOM:532872NSE:SPARC